Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DIALYTE W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intraperitoneal administration of dextrose creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane, while electrolytes in the solution correct imbalances.
The dextrose component provides osmotic pressure for peritoneal dialysis, promoting ultrafiltration of fluid and removal of solutes. Calcium and other electrolytes maintain physiologic balance.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, via continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal: Continuous ambulatory peritoneal dialysis (CAPD): 2-2.5 L per exchange, 4-5 exchanges per day; Continuous cyclic peritoneal dialysis (CCPD): 2-2.5 L per exchange, 3-5 nocturnal exchanges plus one daytime dwell.
None Documented
None Documented
Not applicable (combination product); dextrose follows glucose kinetics (~1.5–2 h); electrolytes have no half-life.
Not applicable as a solution; glucose half-life ~20-30 min in circulation; clinical effect duration corresponds to dwell time (4-6 hours for standard exchange)
Primarily renal; glucose is reabsorbed or metabolized; electrolytes follow renal handling. Not applicable as a drug; dialysate components are removed via peritoneal dialysis effluent.
Primarily eliminated via peritoneal dialysis; glucose is metabolized systemically and excreted as CO2 and water; <5% renal excretion of metabolites
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution